Anna E C Stoelinga, Maarten E Tushuizen, Wilbert B van den Hout, Mar D M Rodriguez Girondo, Elsemieke S de Vries, Amar D Levens, Dirk-Jan A R Moes, Tom J G Gevers, Suzanne van der Meer, Hans T Brouwer, Hendrik J M de Jonge, Ynte S de Boer, Ulrich H W Beuers, Adriaan J van der Meer, Aad P van den Berg, Maureen M J Guichelaar, Joost P H Drenth, Bart van Hoek
BACKGROUND: Autoimmune hepatitis (AIH) is a rare, chronic inflammatory disease of the liver. The treatment goal is reaching complete biochemical response (CR), defined as the normalisation of aspartate and alanine aminotransferases and immunoglobulin gamma. Ongoing AIH activity can lead to fibrosis and (decompensated) cirrhosis. Incomplete biochemical response is the most important risk factor for liver transplantation or liver-related mortality. First-line treatment consists of a combination of azathioprine and prednisolone...
January 17, 2024: Trials